Table 1.
Registered randomized phase II/III trials in locally advanced pancreatic cancer comprising >100 patients.
| Registry Number | Acronym | Phase | Control | Interventions | Primary Outcome | Sample-Size | Centers | Country |
|---|---|---|---|---|---|---|---|---|
| NCT01827553 [33] | CONKO-007 | III | Chemotherapy alone | Chemoradiation + chemotherapy | OS | 830 | Multicenter | Germany |
| NCT02125136 [34] | NEOLAP | II | Gemcitabine-nab-paclitaxel | FOLFIRINOX | Resectability | 168 | Multicenter | Germany |
| NCT03377491 [35] | PANOVA-3 | III | Gemcitabine–nab-paclitaxel | Gemcitabine–nab-paclitaxel + NovoTTF-100L(P) | OS | 556 | Multicenter | Austria, Canada, France, Italy, Spain, Switzerland, USA |
| NCT02806687 [36] | THERGAP-02 | II | Gemcitabine | Gemcitabine + CYL-02 injection | PFS | 100 | Multicenter | France |
| NCT02791503 [37] | CROSSFIRE | III | Chemotherapy + SABR | Chemotherapy + IRE | OS | 138 | Multicenter | The Netherlands |
| NCT01926197 [38] | PANC0015 | III | mFOLFIRINOX | mFOLFIRINOX + SBRT | PFS | 172 | Multicenter | Canada, USA |
| NTR5517 [39] | PELICAN | III | Chemotherapy only | Chemotherapy + RFA | OS | 228 | Multicenter | The Netherlands |
Registered active, randomized, phase II/III interventional studies in LAPC (source: clinicaltrials.gov. and Netherlands Trial Registry, access date 07/01/2019). mFOLFIRINOX: modified FOLFIRINOX; IRE: irreversible electroporation; RFA: radiofrequency ablation; SBRT: stereotactic body radiation therapy; SABR: stereotactic ablative radiotherapy; OS: overall survival; PFS: progression-free survival; LAPC: locally advanced pancreatic cancer.